NewLimit Blog

Home
Archive
About
May // June 2024 Update
Reversing phenotypic age
 • 
Jacob C. Kimmel

June 2024

Markus Grompe is joining our Scientific Advisory Board
We’re excited to announce that Markus Grompe is joining our Scientific Advisory Board to support our Metabolism program.
 • 
Jacob C. Kimmel

May 2024

2024 May Progress Update - Live Event!
The days are long, the years are short
 • 
Jacob C. Kimmel

March 2024

Hao Zhu has joined our Scientific Advisory Board
Alongside the launch of our therapeutic program in hepatic metabolism, we’re excited to welcome Hao to the team.
 • 
Jacob C. Kimmel
January // February 2024 Progress Update
Combinatorial discoveries
 • 
Jacob C. Kimmel

January 2024

2023 Year in Review
Construction ends. The search begins.
 • 
Jacob C. Kimmel

November 2023

September-October 2023 Progress Update
Expanding the palette & compounding returns
 • 
Jacob C. Kimmel

September 2023

July-August 2023 Progress Update
Recursive record setting
 • 
Jacob C. Kimmel

July 2023

May-June 2023 Progress Update
Pure yields
 • 
Jacob C. Kimmel

May 2023

NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
 • 
Brian Armstrong
, 
Blake Byers
, 
Greg Johnson
, and 
Jacob C. Kimmel
April 2023 Progress Update
Overcoming a primary challenge
 • 
Jacob C. Kimmel

March 2023

March 2023 Progress Update - Live Event!
This time with live video
 • 
Jacob C. Kimmel
 and 
Brian Armstrong
© 2024 NewLimit Inc.
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture